Sei Investments Co. Sells 31,743 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sei Investments Co. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 48.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,456 shares of the company’s stock after selling 31,743 shares during the quarter. Sei Investments Co.’s holdings in IDEXX Laboratories were worth $14,244,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at about $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at approximately $31,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $415.87 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $33.71 billion, a P/E ratio of 38.98, a PEG ratio of 3.41 and a beta of 1.39. The stock’s 50 day moving average is $437.07 and its 200 day moving average is $443.27.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.